1-3 of 3
Barbara Wallner, PhD
Close
Sort by
Journal Articles

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Naveen Pemmaraju, MD, Krishna Gundabolu, MBBS, Kristen Pettit, MD, Moshe Talpaz, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Peter Eisenberg, MD, Hagop Youssoufian, MD, Susan Duggan, RN, MBA, Barbara Wallner, PhD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4178.
https://doi.org/10.1182/blood-2019-130310
Published: 2019
Journal Articles

Darinaparsin a Novel Organic Arsenic Molecule Active in Lymphoma: Development of An Oral Form.

Wilson H. Miller, Jr., MD, PhD, Izidore S. Lossos, MD, PhD, Paul R. Conkling, MD, Carlos Becerra, MD, Martin S. Tallman, MD, Jill Buck, Barbara Wallner, PhD, Jonathan Lewis, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 4759.
https://doi.org/10.1182/blood.V114.22.4759.4759
Published: 2009
Journal Articles

ZIO-101, a Novel Organic Arsenic, Inhibits Human Myeloma Cell Growth in a SCID-hu Model.

Richard A. Campbell, Eric Sanchez, Haiming Chen, MD, PhD, Lauren Turker, Mingjie Li, Olivia Trac, Dror Shalitin, Melinda S. Gordon, PhD, Shen Pang, PhD, Benjamin Bonavida, PhD, Jonathan Said, MD, Barbara Wallner, PhD, Robert P. Gale, MD, PhD, James R. Berenson, MD
Journal: Blood
Blood (2006) 108 (11): 3462.
https://doi.org/10.1182/blood.V108.11.3462.3462
Published: 2006